Nature Reviews Endocrinology calls the GIP direction question a 'seeming paradox'

Scientists have identified two distinct brain regions that explain a puzzling pattern seen in obesity research: activating the GIP receptor and blocking it both appear to boost weight loss when combined with GLP-1 receptor drugs. A research highlight in Nature Reviews Endocrinology describes the finding, based on a study published in Nature Metabolism by Lewis and colleagues.^[1]

GLP-1 receptor agonists are the basis of drugs used for type 2 diabetes and weight loss. Adding a GIP receptor component alongside GLP-1 activity increases weight loss compared with GLP-1 alone.^[1] But researchers have also seen that blocking the GIP receptor, rather than activating it, can also increase weight loss when combined with GLP-1 receptor agonism.^[1] Nature Reviews Endocrinology called this a "seeming paradox" because both an on-switch and an off-switch for the same receptor seem to produce the same general outcome.^[1]

To find out why, the study authors used genetically engineered mice in which GIP receptor neurons in a brain region called the area postrema were removed, producing what the paper calls Gipr AP-KO mice.^[1] Regular mice with intact GIP receptor neurons in that region, called Gipr AP-GFP mice, ate less and lost weight after treatment with acyl-GIP, a form of GIP that activates the receptor.^[1] But mice lacking those neurons showed no reduction in food intake or body weight after the same treatment.^[1] This held true even in mice bred to be obese through diet, whose GIP receptor neurons had been knocked out in the area postrema.^[1] The researchers concluded that GIP receptor neurons specifically in the area postrema are responsible for the appetite-suppressing effect of activating the GIP receptor.^[1]

The research highlight notes that the original Nature Metabolism paper goes on to identify a separate brain region responsible for the effects of GIP receptor blockade, distinct from the area postrema circuit tied to GIP receptor activation.^[1] That distinction is the basis for the idea that GIP receptor agonism and antagonism work through different neuron populations rather than simply reversing the same switch.^[1]

Why it matters for patients

This is animal research, done in mice, not a clinical trial in people. The sources describe experiments in engineered mice, not evidence about how any approved or investigational drug performs in humans.^[1] Still, the finding speaks to a real question that has come up as companies develop different types of GIP-targeting drugs alongside GLP-1 drugs, some of which activate the GIP receptor and others of which block it.^[1] Both approaches have shown added weight loss on top of GLP-1 receptor agonism, and this study offers a possible biological explanation: separate brain circuits, not a shared one, may be doing the work.^[1]

For people already taking or considering GLP-1-based medications, this research does not change anything about currently available drugs or their dosing. It is a step toward understanding why certain drug combinations affect appetite and weight, which could eventually inform how future medications are designed and studied. The sources do not report any changes to prescribing information, side effect data, or drug availability tied to this finding.^[1]

What happens next

The underlying study appeared in Nature Metabolism, with the research highlight published in Nature Reviews Endocrinology on August 19, 2026.^[1] The sources do not describe planned follow-up studies in humans or a timeline for when, or whether, these brain-circuit findings might be tested outside of mice.^[1] Readers interested in how this connects to any specific approved or experimental drug will need to watch for further research, since the current sources describe mechanism in animals rather than outcomes in people taking semaglutide, tirzepatide, orforglipron, or other GLP-1-based medicines.^[1]